ArticleJournal of gastrointestinal oncology2025
A novel lactylation-related signature for predicting esophageal cancer prognosis and immune infiltration.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Lactylation Modification and Esophageal Cancer: Research Progress From Hypoxia-Induced Metabolic Reprogramming to Immune Escape.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal cancer (ESCA) is a prevalent malignancy with high morbidity and mortality. It has been demonstrated that lactylation, a novel post-translational modification, is linked to tumor progression and immunity. The objective of this study was to look into the potential role of lactylation-related genes in the prognosis and immune microenvironment of ESCA. Methods: Lactylation-related prognostic genes (LRGs) in ESCA were screened using The Cancer Genome Atlas (TCGA) data. A consensus clustering analysis was conducted on the LRGs, and functional enrichment and immunoassays were performed for different clusters. We utilized least absolute shrinkage and selection operator (LASSO) and multivariate stepwise regression to develop a novel LRG prognostic signature. Subsequently, we assessed the performance of the signature through validation sets. Furthermore, we investigated the immune-related phenotypes of the signature and its response to treatment, as well as its sensitivity to drugs. Finally, experimental verification was performed through immunohistochemical (IHC) staining. Results: We identified 29 LRGs associated with ESCA, and we classified ESCA patients into two lactylation clusters with different prognostic and immune infiltration patterns based on gene expression differences. A new prognostic signature consisting of three prognostic genes ( Conclusions: This study established a new ESCA prognostic signature composed of three lactylation-related genes, which can contribute to predicting prognosis and guiding clinical treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.